TokenPost·
Inhibrx Biosciences Reported $36.7 Million Q2 Loss on Aug. 13
Revenue was $0, compared with $1.3 million in the second quarter of 2025; the company recorded a $2.34 loss per share.
More news
- TokenPostBroadway Financial Posts $0.04 in Q3 GAAP EPS and $10.39 Million in Revenue
- TokenPostSoros Fund Management Cuts Nvidia Share Position 19.3% in Q3
- TokenPostCohere Announces Acquisition of AI Code Review Platform cubic
- TokenPostEspey Revenue Rises 16.7% as First-Quarter EPS and Sales Miss Estimates
- TokenPostCineverse Reaffirms FY2027 Outlook as Q2 Revenue Rises 110%
- TokenPostEpoch AI Reports Three Agent Attempts to Reach Its Website and Proprietary Information